Advertisement

Estetrol is not a SERM but a NEST and has a specific safety profile on coagulation

  • Jonathan Douxfils
    Correspondence
    Corresponding author at: University of Namur, Faculty of Medicine, Department of Pharmacy, Namur Research Institute for Life Sciences (NARILIS), Clinical Pharmacology Research Group, Namur, Belgium.
    Affiliations
    University of Namur, Faculty of Medicine, Department of Pharmacy, Namur Research Institute for Life Sciences (NARILIS), Clinical Pharmacology Research Group, Namur, Belgium

    Qualiblood sa, Namur, Belgium
    Search for articles by this author
  • Laure Morimont
    Affiliations
    University of Namur, Faculty of Medicine, Department of Pharmacy, Namur Research Institute for Life Sciences (NARILIS), Clinical Pharmacology Research Group, Namur, Belgium

    Qualiblood sa, Namur, Belgium
    Search for articles by this author
  • Ulysse Gaspard
    Affiliations
    Department of Obstetrics and Gynecology, University of Liège, Belgium
    Search for articles by this author
  • Wulf H. Utian
    Affiliations
    Case Western Reserve University School of Medicine, Cleveland, OH, United States of America
    Search for articles by this author
  • Jean-Michel Foidart
    Affiliations
    Estetra SRL, An affiliate's Company of Mithra Pharmaceuticals, Liège, Belgium

    University of Liège, Liège, Belgium
    Search for articles by this author
Published:September 15, 2022DOI:https://doi.org/10.1016/j.thromres.2022.09.007
      We read with interest the article of Booyens et al. discussing the risk of venous thromboembolism (VTE) with hormonal replacement therapy (HRT) [
      • Booyens R.M.
      • Engelbrecht A.-M.
      • Strauss L.
      • Pretorius E.
      To clot, or not to clot: the dilemma of hormone treatment options for menopause.
      ]. This article nicely summarized over 80 years of HRT development for the relief of menopausal symptoms, but we observed some approximations which, in our opinion, need to be highlighted.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Thrombosis Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Booyens R.M.
        • Engelbrecht A.-M.
        • Strauss L.
        • Pretorius E.
        To clot, or not to clot: the dilemma of hormone treatment options for menopause.
        Thromb. Res. 2022; 218: 99-111https://doi.org/10.1016/j.thromres.2022.08.016
        • Gerard C.
        • Arnal J.F.
        • Jost M.
        • Douxfils J.
        • Lenfant F.
        • Fontaine C.
        • Houtman R.
        • Archer D.F.
        • Reid R.L.
        • Lobo R.A.
        • Gaspard U.
        • Coelingh Bennink H.J.T.
        • Creinin M.D.
        • Foidart J.M.
        Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause.
        Expert. Rev. Clin. Pharmacol. 2022; 15: 121-137
        • Douxfils J.
        • Morimont L.
        • Bouvy C.
        Oral contraceptives and venous thromboembolism: focus on testing that may enable prediction and assessment of the risk.
        Semin. Thromb. Hemost. 2020; 46: 872-886
        • Cushman M.
        • Larson J.C.
        • Rosendaal F.R.
        • Heckbert S.R.
        • Curb J.D.
        • Phillips L.S.
        • Baird A.E.
        • Eaton C.B.
        • Stafford R.S.
        Biomarkers, menopausal hormone therapy and risk of venous thrombosis: the Women's Health Initiative.
        Res. Pract. Thromb. Haemost. 2018; 2: 310-319
        • Douxfils J.
        • Lobo R.
        • Taziaux M.
        • Jost M.
        • Bouvy C.
        • Gaspard U.
        • Foidart J.M.
        Estetrol (E4) is a native fetal estrogen that does not modify coagulation markers in postmenopausal women and maintains sensitivity to activated protein C (APC).
        Maturitas. 2021; 152: 69https://doi.org/10.1016/j.maturitas.2021.08.013
        • Douxfils J.
        • Morimont L.
        • Delvigne A.S.
        • Devel P.
        • Masereel B.
        • Haguet H.
        • Bouvy C.
        • Dogne J.M.
        Validation and standardization of the ETP-based activated protein C resistance test for the clinical investigation of steroid contraceptives in women: an unmet clinical and regulatory need.
        Clin. Chem. Lab. Med. 2020; 58: 294-305
        • Douxfils J.
        • Klipping C.
        • Duijkers I.
        • Kinet V.
        • Mawet M.
        • Maillard C.
        • Jost M.
        • Rosing J.
        • Foidart J.M.
        Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters.
        Contraception. 2020; 102: 396-402
        • Post M.S.
        • Rosing J.
        • Mooren M.J.Van Der
        • Zweegman S.
        • Baal W.M.Van
        • Kenemans P.
        • Stehouwer C.D.
        • Ageing W.
        • U. the Institute for Cardiovascular Research-Vrije
        Increased resistance to activated protein C after short-term oral hormone replacement therapy in healthy post-menopausal women.
        Br. J. Haematol. 2002; 119: 1017-1023
        • Post M.S.
        • Christella M.
        • Thomassen L.G.
        • van der Mooren M.J.
        • van Baal W.M.
        • Rosing J.
        • Kenemans P.
        • Stehouwer C.D.
        Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women.
        Arterioscler. Thromb. Vasc. Biol. 2003; 23: 1116-1121
        • Morimont L.
        • Jost M.
        • Gaspard U.
        • Foidart J.M.
        • Dogne J.M.
        • Douxfils J.
        Low thrombin generation in users of a contraceptive containing estetrol and drospirenone.
        J. Clin. Endocrinol. Metab. 2022; (In press)https://doi.org/10.1210/clinem/dgac511